# A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

> **NCT06525220** · PHASE3 · RECRUITING · sponsor: **Merus B.V.** · enrollment: 700 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Petosemtamab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06525220
- **Lead sponsor:** Merus B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-25
- **Primary completion:** 2028-01
- **Final completion:** 2030-07
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06525220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06525220, "A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT06525220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*